Robert W. Baird & Co. Incorporated on Axsome Therapeutics
Thesis
Baird initiated a position in Axsome Therapeutics as one of three commercial-stage therapeutics companies added during the quarter. Axsome already has multiple marketed products, reducing its dependence on a single development-stage asset. Baird identifies the recently approved Auvelity therapy as the company's most exciting growth opportunity, particularly for agitation associated with dementia and Alzheimer's disease.
“the most exciting growth opportunity is its recently approved therapy Auvelity”